Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 9,520 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Recruiting Phase 3 Interventional

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
15,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
357
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 284 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

NCT01316900
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444, tiotropium bromide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Gestational Diabetes Screening in the Gravid Obese Woman

NCT01864564
View directory record Official record
Conditions
Gestational Diabetes, Obesity
Interventions
Early Screen
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
962 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 26, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

Study of Tazemetostat in Lymphoid Malignancies

NCT05983965
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
Tazemetostat
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 26, 2026, 5:30 AM EDT
Terminated No phase listed Observational Results available

A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

NCT01243892
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
NuSpin, Somatropin
Device · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
2 Years to 14 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 26, 2026, 5:30 AM EDT
Completed No phase listed Observational Results available

Postmarket Registry for Evaluation of the Superion® Spacer

NCT04087811
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
Superion® Indirect Decompression System (IDS)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
45 Years and older
Enrollment
1,674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

NCT00559871
View directory record Official record
Conditions
Parkinson's Disease
Interventions
fipamezole
Drug
Lead sponsor
Juvantia Pharma Ltd
Industry
Eligibility
30 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 26, 2026, 5:30 AM EDT
Withdrawn No phase listed Observational

Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy

NCT00083044
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Oct 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444
View directory record Official record
Conditions
Chronic Migraine
Interventions
Botulinum toxin type A, Placebo
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT01555463
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

NCT01663987
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Florence, Alabama • Fountain Valley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

NCT04055428
View directory record Official record
Conditions
Diabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Natriuretic Peptides, Metabolism, Energy Expenditure
Interventions
Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
Drug · Other · Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

NCT00657007
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab, Placebo
Biological
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

NCT04042844
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
BRTX-100, Saline
Biological · Drug
Lead sponsor
BioRestorative Therapies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Santa Monica, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
479
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults

NCT06284681
View directory record Official record
Conditions
Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Interventions
Weight-focused health coaching, Weight-neutral health coaching, Intensify lifestyle approach, Augment with enhanced medical management
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

NCT01745367
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Tivozanib Hydrochloride, paclitaxel, Placebo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 26, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 26, 2026, 5:30 AM EDT
Terminated Phase 2 Interventional Results available

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

NCT04849364
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Capecitabine, Talazoparib, Pembrolizumab, Inavolisib
Drug
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional

Sedation Management in Pediatric Patients With Acute Respiratory Failure (The RESTORE Study)

NCT00814099
View directory record Official record
Conditions
Respiratory Insufficiency, Respiratory Distress Syndrome, Newborn, Lung Diseases
Interventions
Team approach to sedation management, Usual approach to sedation management
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Weeks to 18 Years
Enrollment
2,449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

FREE Study - Fracture Reduction Evaluation

NCT00211211
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Multiple Myeloma, Bone Neoplasms
Interventions
Balloon Kyphoplasty
Device
Lead sponsor
Medtronic Spine LLC
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 26, 2026, 5:30 AM EDT